Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety
Kolbinger F, Di Padova F, Deodhar A, Hawkes JE, Huppertz C, Kuiper T, McInnes IB, Ritchlin CT, Rosmarin D, Schett G, Carballido JM, Häusermann P, Calonder C, Vogel B, Rondeau JM, Bruin G (2021)
Publication Type: Journal article, Review article
Publication year: 2021
Journal
Article Number: 107925
DOI: 10.1016/j.pharmthera.2021.107925
Abstract
Psoriasis, psoriatic arthritis, and axial spondyloarthritis are systemic inflammatory diseases, each commonly manifesting as a spectrum of symptoms, complications, and comorbidities that arise differently in individual patients. Drugs targeting inflammatory cytokines common to the pathogenesis of each of these conditions have been developed, although their specific actions in the different tissues involved are variable. For a drug to be effective, it must be efficiently delivered to and locally bioactive in disease-relevant tissues. Detailed clinical data shed light on the therapeutic effects of individual biologics on specific domains or clinical manifestations of disease and assist in guiding treatment decisions. Pharmacologic, molecular, and functional properties of drugs strongly impact their observed safety and efficacy, and an understanding of these properties provides complementary insight. Secukinumab, a fully human monoclonal IgG1/κ antibody selectively targeting interleukin (IL)-17A, has been in clinical use for >6 years in the treatment of moderate to severe psoriasis, psoriatic arthritis, and both radiographic (also known as ankylosing spondylitis) and nonradiographic axial spondyloarthritis. In this review, we discuss pharmacokinetic and pharmacodynamic data for secukinumab to introduce clinicians to the pharmacological properties of this widely used drug. Understanding how these properties affect the observed clinical efficacy, safety, and tolerability of this drug in the treatment of IL-17A–mediated systemic inflammatory diseases is important for all physicians treating these conditions.
Authors with CRIS profile
Involved external institutions
Novartis AG
Switzerland (CH)
Oregon Health and Science University (OSHU)
United States (USA) (US)
University of California Davis (UCDAVIS)
United States (USA) (US)
University of Glasgow
United Kingdom (GB)
University of Rochester Medical Center Rochester, NY
United States (USA) (US)
Tufts Medical Center
United States (USA) (US)
Universitätsspital Basel
Switzerland (CH)
Switzerland (CH)
Oregon Health and Science University (OSHU)
United States (USA) (US)
University of California Davis (UCDAVIS)
United States (USA) (US)
University of Glasgow
United Kingdom (GB)
University of Rochester Medical Center Rochester, NY
United States (USA) (US)
Tufts Medical Center
United States (USA) (US)
Universitätsspital Basel
Switzerland (CH)
How to cite
APA:
Kolbinger, F., Di Padova, F., Deodhar, A., Hawkes, J.E., Huppertz, C., Kuiper, T.,... Bruin, G. (2021). Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2021.107925
MLA:
Kolbinger, Frank, et al. "Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety." Pharmacology & Therapeutics (2021).
BibTeX: Download